GLP-1 Receptor Agonists: Mechanisms in Metabolic Health
Glucagon-like peptide-1 receptor agonists influence glucose regulation, appetite, and weight through central and peripheral pathways well-characterized in the peer-reviewed literature.
GLP-1 is an incretin hormone secreted by intestinal L-cells in response to nutrient intake. GLP-1 receptor agonists mimic this signal, enhancing glucose-dependent insulin secretion, slowing gastric emptying, and acting on hypothalamic centers to reduce appetite.
Multiple randomized trials summarized in open-access reviews have demonstrated meaningful effects on glycemic control and body weight in adults with type 2 diabetes and obesity. Side-effect profiles and contraindications make physician oversight essential.
Key takeaways
- GLP-1 agonists act on both pancreas and brain.
- Clinical benefits are well-documented for diabetes and obesity.
- Therapy requires medical screening and ongoing monitoring.
Educational only. Not medical advice. SEIVA protocols are prescribed only after physician review and telehealth consultation.